Publication: Population pharmacokinetic properties of sulfadoxine and pyrimethamine: A pooled analysis to inform optimal dosing in african children with uncomplicated malaria
Issued Date
2018-05-01
Resource Type
ISSN
10986596
00664804
00664804
Other identifier(s)
2-s2.0-85046032073
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Antimicrobial Agents and Chemotherapy. Vol.62, No.5 (2018)
Suggested Citation
Miné de Kock, Joel Tarning, Lesley Workman, Elizabeth N. Allen, Mamadou M. Tekete, Abdoulaye A. Djimde, David J. Bell, Steve A. Ward, Karen I. Barnes, Paolo Dentia Population pharmacokinetic properties of sulfadoxine and pyrimethamine: A pooled analysis to inform optimal dosing in african children with uncomplicated malaria. Antimicrobial Agents and Chemotherapy. Vol.62, No.5 (2018). doi:10.1128/AAC.01370-17 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/46735
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Population pharmacokinetic properties of sulfadoxine and pyrimethamine: A pooled analysis to inform optimal dosing in african children with uncomplicated malaria
Other Contributor(s)
Abstract
© 2018 de Kock et al. Sulfadoxine-pyrimethamine with amodiaquine is recommended by the World Health Organization as seasonal malaria chemoprevention for children aged 3 to 59 months in the sub-Sahel regions of Africa. Suboptimal dosing in children may lead to treatment failure and increased resistance. Pooled individual patient data from four previously published trials on the pharmacokinetics of sulfadoxine and pyrimethamine in 415 pediatric and 386 adult patients were analyzed using nonlinear mixed-effects modeling to evaluate the current dosing regimen and, if needed, to propose an optimized dosing regimen for children under 5 years of age. The population pharmacokinetics of sulfadoxine and pyrimethamine were both best described by a one-compartment disposition model with first-order absorption and elimination. Body weight, age, and nutritional status (measured as the weight-for-age Z-score) were found to be significant covariates. Allometric scaling with total body weight and the maturation of clearance in children by postgestational age improved the model fit. Underweight-for-age children were found to have 15.3% and 26.7% lower bioavailabilities of sulfadoxine and pyrimethamine, respectively, for each Z-score unit below 2. Under current dosing recommendations, simulation predicted that the median day 7 concentration was below the 25th percentile for a typical adult patient (50 kg) for sulfadoxine for patients in the weight bands of 8 to 9, 19 to 24, 46 to 49, and 74 to 79 kg and for pyrimethamine for patients in the weight bands of 8 to 9, 14 to 24, and 42 to 49 kg. An evidence-based dosing regimen was constructed that would achieve sulfadoxine and pyrimethamine exposures in young children and underweight-for-age young children that were similar to those currently seen in a typical adult.